Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Coronavirus Infection and Hematologic Diseases
- Sponsor
- National Research Center for Hematology, Russia
- Enrollment
- 666
- Locations
- 13
- Primary Endpoint
- 30-day all-cause mortality
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
Detailed Description
This is a web-based registry. After registration, physicians from hematology clinical centers and hospitals in Russia will receive access to the web platform for clinical trial management to fill in the online data collection form in a de-identified manner. This form includes questions about general clinical history of hematologic disease, manifestation, treatment, and the course of COVID-19, concomitant conditions, consequences on the hematologic disease, short-term and long-term outcomes. It will take approximately 10 min to answer the questions. Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for hematologic disease outcomes and overall survival assessment.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
30-day all-cause mortality
Time Frame: 30 day
Rate of death from any cause
Secondary Outcomes
- Relapse or progression of hematologic disease(30 day, 90 day and 180 day)
- Overall survival(30 day, 90 day and 180 day)
- ICU admission(30 day)
- COVID-19 complications(30 day)
- Mechanical ventilation / O2 requirement(30 day)
- Risk factors(30 day, 90 day and 180 day)